Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1975245 | 1.00 | CA1 (0.32) | CA1CA2CA4ALDH1A1 | |
| SCHEMBL6299469 | 1.00 | CA1 (0.32) | CA1CA2CA4ALDH1A1 | |
| SCHEMBL1975244 | 1.00 | CA1 (0.32) | CA1CA2CA4ALDH1A1 | |
| SCHEMBL2548263 | 0.92 | — | — | |
| SCHEMBL8728380 | 0.85 | TDP1 (0.41) | CA1CA2CA4 | |
| SCHEMBL13670463 | 0.85 | — | — | |
| SCHEMBL8344814 | 0.84 | — | — | |
| SCHEMBL4104342 | 0.84 | — | — | |
| SCHEMBL8213682 | 0.81 | — | — | |
| SCHEMBL17451026 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292224-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2019-09-26 | — | — | US | disclosed |
| US-10328117-B2 | Bis-sulfhydryl macrocyclization systems | AILERON THERAPEUTICS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20190185518-A9 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | AILERON THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
| US-10300109-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10227380-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20190071469-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2019-03-07 | — | — | US | disclosed |
| US-10022422-B2 | Peptidomimetic macrocycles | Alleron Therapeutics, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023613-B2 | Peptidomimetic macrocycles as modulators of MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022422-B2 | Peptidomimetic macrocycles | Alleron Therapeutics, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180085426-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2018-03-29 | — | — | US | disclosed |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009149214-A2 | COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR TRANSPORT OF BIOMOLECULES | AILERON THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090088553-A1 | Bis-Sulfhydryl Macrocyclization Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088553-A1 | Bis-Sulfhydryl Macrocyclization Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090047711-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047711-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008076904-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023613-B2 | Peptidomimetic macrocycles as modulators of MCL-1 | MCL1, BCL2L1, BCL2L11 | CA1 4418/4885CA2 4737/4885CA4 4883/4885 |
| US-20090326192-A1 | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES | VIP, ANPEP, DNPEP | CA1 3259/4885CA2 3748/4885CA4 3418/4885 |
| US-20180085426-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | CA1 2330/4885CA2 2741/4885CA4 2415/4885 |
| US-20090088553-A1 | Bis-Sulfhydryl Macrocyclization Systems | CBS, HLCS, CTH | CA1 2044/4885CA2 2681/4885CA4 3358/4885 |
| US-20090047711-A1 | BIS-SULFHYDRYL MACROCYCLIZATION SYSTEMS | CBS, HLCS, CTH | CA1 2044/4885CA2 2681/4885CA4 3358/4885 |
| US-10328117-B2 | Bis-sulfhydryl macrocyclization systems | CBS, HLCS, SCLY | CA1 1890/4885CA2 3052/4885CA4 3622/4885 |
| US-20190071469-A1 | THERAPEUTIC PEPTIDOMIMETIC MACROCYCLES | PCNA, MKI67, NFATC1 | CA1 4416/4885CA2 4308/4885CA4 3926/4885 |
| US-20190185518-A9 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | BCL2L11, BCL2L1, BCL2L13 | CA1 3103/4885CA2 3931/4885CA4 4692/4885 |
| US-20190292224-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | CA1 3190/4885CA2 4345/4885CA4 3179/4885 |
| US-10227380-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | IL33, TPR, CDC37 | CA1 3190/4885CA2 4345/4885CA4 3179/4885 |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | PCNA, MKI67, NFATC1 | CA1 4416/4885CA2 4308/4885CA4 3926/4885 |
| US-10300109-B2 | Peptidomimetic macrocycles | TCF4, CTNNB1, WNT1 | CA1 3510/4885CA2 4577/4885CA4 1845/4885 |
| US-10022422-B2 | Peptidomimetic macrocycles | HAVCR2, ZC3HAV1, ZC3HAV1L | CA1 3641/4885CA2 3758/4885CA4 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.